Hansa Biopharma AB

Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies

Fri, Nov 13, 2015 08:45 CET

At Hansa Medical’s Capital Markets Day in Stockholm today, one of the world’s leading transplantation experts, Professor Stanley Jordan at Cedars-Sinai Medical Center, Los Angeles, will show data from one of his ongoing studies where highly sensitized patients are desensitized and treated with Hansa Medical’s lead candidate drug IdeS prior to transplantation.Data will be shown from a patient with a PRA level of 100% who was treated and transplanted successfully in July this year. The investigator-sponsored clinical phase II study, which was initiated and led by Dr. Jordan, is an open-

First patient in IdeS study at Cedars-Sinai Medical Center in Los Angeles receives kidney transplantation

Tue, Aug 11, 2015 08:00 CET

Hansa Medical AB (publ) today announced that the first patient in an investigator-sponsored Phase II clinical study at Cedars-Sinai Medical Center in Los Angeles, California, has been treated with IdeS and subsequently transplanted.The study is an open-label study to assess the safety and efficacy of IdeS in eliminating donor specific antibodies and thus prevent antibody-mediated rejection in highly sensitized patients. The study will include up to 20 highly sensitized patients on the UNOS (United Network for Organ Sharing) waiting list. The principal investigator, Professor Stanley

Contacts

Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies

First patient in IdeS study at Cedars-Sinai Medical Center in Los Angeles receives kidney transplantation

Subscribe

Media

Share

Contacts

Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies

First patient in IdeS study at Cedars-Sinai Medical Center in Los Angeles receives kidney transplantation

Subscribe

Media